Novo Says May Take Years to Comply With FDA Request

Feb. 11 (Bloomberg) -- Novo Nordisk A/S Chief Executive Officer Lars Rebien Soerensen discusses the U.S. Food and Drug Administration's decision not to approve the insulin maker's Tresiba diabetes treatment, saying more data on heart safety is needed. He talks from Copenhagen with Francine Lacqua on Bloomberg Television's "On the Move." (Source: Bloomberg)
Is Virtual Reality the Next Mega-Trend in Tech?
01:31 - Piper Jaffray's Gene Munster and Canaan Partners' Maha Ibrahim discuss the future of virtual reality with Bloomberg Businessweek's Brad Stone on "Bloomberg West." (Source: Bloomberg)
  • Tech, Financials to Be Rediscovered in 2-3 Years: Lee
  • Week in Review: U.S. GDP Shrinks 0.7% in 1Q
  • Humana Soars as Possible Sale Explored